These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 19414675

  • 1. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
    Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.
    J Clin Oncol; 2009 Jun 20; 27(18):3036-43. PubMed ID: 19414675
    [Abstract] [Full Text] [Related]

  • 2. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF.
    J Immunother; 2010 Jun 20; 33(2):178-84. PubMed ID: 20145546
    [Abstract] [Full Text] [Related]

  • 3. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
    Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW.
    J Clin Oncol; 2014 Jun 10; 32(17):1797-803. PubMed ID: 24799467
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
    Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouillé V, Quittet P, Klein B, Rossi JF.
    J Clin Oncol; 2008 Jun 01; 26(16):2725-31. PubMed ID: 18427151
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 6. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.
    Ann Oncol; 1999 Jun 10; 10(6):655-61. PubMed ID: 10442187
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM.
    Leuk Lymphoma; 2010 Jul 10; 51(7):1241-50. PubMed ID: 20496994
    [Abstract] [Full Text] [Related]

  • 8. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
    Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R.
    Leuk Lymphoma; 2009 Jan 10; 50(1):37-46. PubMed ID: 19125383
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 10; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 10. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K.
    J Cancer Res Clin Oncol; 2001 Oct 10; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract] [Full Text] [Related]

  • 11. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 10; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

  • 12. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R.
    J Clin Oncol; 2000 Sep 10; 18(17):3135-43. PubMed ID: 10963642
    [Abstract] [Full Text] [Related]

  • 13. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun 10; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 14. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
    Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G.
    Bone Marrow Transplant; 2002 Feb 10; 29(4):303-12. PubMed ID: 11896427
    [Abstract] [Full Text] [Related]

  • 15. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, Repasky EA, Czuczman MS.
    Leuk Lymphoma; 2005 Dec 10; 46(12):1775-84. PubMed ID: 16263581
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW, Young HA, Pennington RW, Weeks SD.
    Proc Natl Acad Sci U S A; 1996 Oct 01; 93(20):10972-7. PubMed ID: 8855293
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.
    J Clin Oncol; 2002 May 15; 20(10):2453-63. PubMed ID: 12011122
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [Abstract] [Full Text] [Related]

  • 19. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
    Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R.
    J Clin Oncol; 2020 Jul 01; 38(19):2160-2169. PubMed ID: 32343642
    [Abstract] [Full Text] [Related]

  • 20. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F, Cotto M, Liboy I, Rivera E, Pavia OA, Bruno M.
    Leuk Lymphoma; 2012 Oct 01; 53(10):1929-33. PubMed ID: 22448918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.